What are the causes of hepatorenal syndrome in patients with advanced liver disease, particularly cirrhosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Causes of Hepatorenal Syndrome

Hepatorenal syndrome develops from the combination of advanced cirrhosis with portal hypertension causing splanchnic vasodilation, which leads to effective arterial underfilling and compensatory renal vasoconstriction, often precipitated by bacterial infections or other acute insults. 1, 2

Primary Underlying Mechanism

The fundamental cause is cirrhosis with portal hypertension, which creates a cascade of hemodynamic disturbances 1:

  • Splanchnic arterial vasodilation is the primary event, causing reduction in effective arterial blood volume despite total plasma volume expansion 1, 3
  • Increased sinusoidal hydrostatic pressure from portal hypertension drives lymph formation and ascites development 1, 3
  • Effective arterial underfilling triggers activation of the sympathetic nervous system and renin-angiotensin-aldosterone system (RAAS), leading to intense renal vasoconstriction 1, 2
  • Impaired cardiac function from cirrhotic cardiomyopathy prevents adequate compensation for the vasodilation 2, 3

Major Precipitating Factors

While cirrhosis creates the substrate, specific triggers commonly precipitate HRS 1, 2:

Bacterial Infections (Most Important)

  • Spontaneous bacterial peritonitis (SBP) is the single most important precipitant, causing HRS in approximately 30% of cases 2, 4
  • Bacterial products and cytokines induce further splanchnic vasodilation, worsening circulatory dysfunction 1
  • Bacterial products directly alter renal peritubular microcirculation and cause oxidative stress 1

Volume Depletion

  • Aggressive diuretic use without adequate monitoring 1
  • Large-volume paracentesis without albumin replacement 1
  • Gastrointestinal bleeding causing hypovolemia 1

Nephrotoxic Insults

  • NSAIDs are particularly dangerous in cirrhotic patients 2
  • Aminoglycosides and other nephrotoxic antibiotics 2
  • Iodinated contrast media 2

Other Precipitants

  • Severe alcoholic hepatitis 4
  • Hepatocellular carcinoma with vascular invasion or severe cholestasis 3
  • Any acute deterioration in liver function 1

Advanced Pathophysiological Contributors

Beyond the primary hemodynamic mechanisms, additional factors contribute 3, 5:

  • Systemic inflammation is increasingly recognized as a key feature, with inflammatory signals affecting proximal tubular cells and causing mitochondrial dysfunction 3, 5
  • Increased synthesis of vasoactive mediators including cysteinyl leukotrienes, thromboxane A2, F2-isoprostanes, and endothelin-1 affects renal blood flow 3
  • Increased gut permeability from portal hypertension allows bacterial translocation, contributing to systemic inflammation 1

Important Clinical Context

HRS accounts for only 15-43% of AKI cases in cirrhotic patients—other common causes include hypovolemia (27-50%) and acute tubular necrosis (14-35%) 2. This is a critical pitfall: not all kidney injury in cirrhosis is HRS, and distinguishing these entities is essential because vasoconstrictors are not indicated for ATN 5, 6.

Despite being classified as "functional" renal failure, severe or repeated episodes of renal hypoperfusion can lead to structural kidney damage over time, exposing patients to direct hemodynamic injury 1, 3. This challenges the traditional view of HRS as purely reversible and suggests HRS and ATN may represent a continuum rather than distinct entities 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Criteria for Hepatorenal Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pathophysiology and Clinical Considerations of Hepatorenal Syndrome in Hepatocellular Carcinoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Hepatorenal Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hepatorenal Syndrome.

Clinical journal of the American Society of Nephrology : CJASN, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.